Principia Biopharma Inc. announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello previously was president of the Americas, Hematology and Oncology at Celgene Corporation. With more than 30 years of experience in the pharmaceutical and biotech industries, Ms. Tomasello has substantial commercial and strategic experience. From 2015 to 2018, Ms. Tomasello was chief commercial officer at leading immuno-oncology cell therapy company Kite Pharma, which was acquired by Gilead Sciences. Prior to this, she served as chief commercial officer and oversaw the launch of Imbruvica at Pharmacyclics Inc., which was subsequently acquired by AbbVie Inc. Ms. Tomasello previously was president of the Americas, Hematology and Oncology at Celgene Corporation where she managed over $4 billion in product revenues and was instrumental in various global expansion and acquisition strategies. She has also held senior positions at Genentech, Pfizer Laboratories, Miles Pharmaceuticals and Procter & Gamble.